Shots: The NMPA has approved a P-I/II SWATCH dose-escalation & dose-expansion study that evaluates the safety, tolerability, and preliminary efficacy of selinexor in combination with the R2 regimen of lenalidomide […]readmore
Tags : P-I/II
Shots: The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26, 2021 cutoff data The preliminary efficacy analysis […]readmore
Shots: The companies collaborated to evaluate Mirati’s adagrasib (KRASG12C inhibitor) + Sanofi’s SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations Adagrasib & […]readmore
Shots: The P-I/II dose expansion studies evaluate the safety & preliminary anti-tumor efficacy of VT1021 as monothx. in patients with dose-escalation & expansion cohorts with rGBM & PC. The results […]readmore
Shots: The P-I/II KRYSTAL–1 study evaluates adagrasib (600mg, bid) as monothx. and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation following prior systemic […]readmore
In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment […]readmore
Shots: The FDA’s clinical hold is based on interim safety findings from a pre-clinical study which showed that 6/7 animals treated with BMN 307 (2e14 Vg/kg) had tumors on liver […]readmore
Shots: The companies collaborated to evaluate Treos’ PolyPEPI1018 (Polypeptide cancer immunotherapy) + Roche’s atezolizumab (PD-L1-inhibitor) in P-I/II trial in patients with late-stage MSS mCRC which is expected to initiate in […]readmore
Shots: A sub-analysis from the Oxford’ P-I/II COV001 & P-II/III COV002 trials for Vaxzevria (as single or two doses) in patients aged 18 to 55yrs., demonstrated strong immune responses following […]readmore
Shots: The companies reported the initiation of P-I/II trial to evaluate the safety, tolerability, and immunogenicity of MRT5500 (1 or 2doses given 21 days apart) vs PBO in ~415 healthy […]readmore